Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma
Conclusion Goserelin therapy reduces serum levels of inflammatory cytokines, tumour necrosis factor- α and monocyte chemotactic protein-1, improving leiomyoma-related symptoms with good tolerability in patients with uterine leiomyoma.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Hormones | Iraq Health | Leiomyoma | Middle East Health | OBGYN | Pain | Pain Management | Study | Teaching | Teaching Hospitals | Universities & Medical Training